Abstract

Pulmonary Hypertension (PH), the syndrome of elevated pressure in the pulmonary arteries, is associated with significant morbidity and mortality for affected children. PH is associated with a wide variety of potential underlying causes, including cardiac, pulmonary, hematologic and rheumatologic abnormalities. Regardless of the cause, for many patients the natural history of PH involves progressive elevation in pulmonary arterial resistance and pressure, right ventricular dysfunction, and eventually heart failure. In recent years, a number of pulmonary arterial hypertension (PAH)-targeted therapies have become available to reduce pulmonary artery pressure and improve outcome. A growing body of evidence in both the adult and pediatric literature demonstrates enhanced quality of life, functional status, and survival among treated patients. This review provides a description of select etiologies of PH seen in pediatrics and an update on the most recent data pertaining to evaluation and management of children with PH/PAH. The available evidence for specific classes of PAH-targeted therapies in pediatrics is additionally discussed.

Highlights

  • Untreated, pulmonary arterial hypertension (PAH) in children carries a poor prognosis

  • In 1999, a study by Barst et al showed that survival for children with severe idiopathic PAH (IPAH) who were candidates for intravenous prostacyclin but were unable to be treated with this therapy was poor (45% and 29% at 1 and 4 years, respectively) [2]

  • Unlike what is seen among adult patients, pediatric pulmonary hypertension is intrinsically linked to lung growth and development [6]

Read more

Summary

Introduction

Pulmonary arterial hypertension (PAH) in children carries a poor prognosis. For patients whose disease progresses despite maximal medical therapy, the surgical options include lung transplantation or a Potts shunt—creation of a left pulmonary artery to descending aorta connection in an effort to facilitate right-to-left shunting [9]. This procedure can provide effective palliation in carefully selected children with end-stage pulmonary vascular disease and suprasystemic PAH [10]. Patients compiled at 3 pulmonary hypertension (PH) centers (Denver, New York, Netherlands): 1-, 3-, 5- and 7-year transplantation-free survival rates were 96%, 89%, 81% and 79%, respectively [4]

Definition
Epidemiology
Prognosis
Single-Ventricle Circulation
Bronchopulmonary Dysplasia
Standard Evaluation
Emerging Evaluation Techniques
Cardiac Catheterization and Acute Vasoreactivity Testing
Targeted Pharmacological Therapy for PAH
Calcium Channel Blockers
Prostacyclins
Endothelin Receptor Antagonists
Phosphodiesterase-5 Inhibitors and Soluble Guanylate Cyclase Stimulators
Combination Therapy
10. Atrial Septostomy and Potts Shunt for Refractory PAH
11. Transplantation
12. Adjunctive Therapy
Findings
13. Summary
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.